Xenon Pharmaceuticals Inc. $XENE Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 70.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,425,492 shares of the biopharmaceutical company’s stock after selling 3,404,149 shares during the period. Wellington Management Group LLP owned about 1.47% of Xenon Pharmaceuticals worth $86,043,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Xenon Pharmaceuticals during the second quarter worth $454,057,000. Avoro Capital Advisors LLC grew its position in shares of Xenon Pharmaceuticals by 0.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after purchasing an additional 24,444 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter worth about $252,673,000. Janus Henderson Group PLC increased its stake in shares of Xenon Pharmaceuticals by 2.3% during the first quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock worth $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Finally, Capital International Investors raised its position in shares of Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after purchasing an additional 233,466 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $60.00 on Wednesday. The stock has a market cap of $5.80 billion, a P/E ratio of -12.66 and a beta of 0.62. The stock’s 50 day simple moving average is $63.40 and its 200-day simple moving average is $56.73. Xenon Pharmaceuticals Inc. has a 1-year low of $35.60 and a 1-year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period last year, the firm posted ($1.07) earnings per share. As a group, research analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. HC Wainwright reiterated a “buy” rating and set a $74.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, August 10th. Finally, Royal Bank Of Canada reduced their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and an average target price of $77.13.

Insider Buying and Selling

In other news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher John Kenney sold 7,068 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the sale, the insider directly owned 2 shares of the company’s stock, valued at $120.50. This represents a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 19,580 shares of company stock valued at $1,199,935 over the last 90 days. Insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.